Clinical evaluation of a new antilithiatic drug, "Debelysin"

"Debelysin", a new antinephrolithiatic drug, was administered in 5-ml oral doses, 3 times daily: to 30 nephrolithiatic patients for 6 months, and to 30 patients with surgically removed renal calculi for 12 months. "Debelysin" showed diuretic action which affected neither the electrolyte nor the acid-alkaline balance. The majority of patients responded to "Debelysin" with a decrease in diurnal calciuria and phosphaturia. During the treatment the calculi did not increase in size and the recurrence of the lithiasis was not observed. No toxic and clinical side effects of "Debelysin" were noted.